Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01304420
Other study ID # 10439
Secondary ID
Status Completed
Phase Phase 0
First received January 7, 2011
Last updated March 21, 2012
Start date October 2009
Est. completion date November 2011

Study information

Verified date March 2012
Source University of Aarhus
Contact n/a
Is FDA regulated No
Health authority Denmark: The Regional Committee on Biomedical Research Ethics
Study type Observational

Clinical Trial Summary

The purpose of this study is to analyse the usability of ultrasonography together with biomarkers in the investigation of patients diagnosed with juvenile idiopathic arthritis. The investigators hypothesize that serum and urine markers of cartilage and bone synthesis and degradation, together with ultrasound measurements of joint cartilage thickness, are useful tools in the early evaluation of JIA patients, - as diagnostic, prognostic and monitoring methods.


Recruitment information / eligibility

Status Completed
Enrollment 95
Est. completion date November 2011
Est. primary completion date November 2011
Accepts healthy volunteers No
Gender Both
Age group 5 Years to 15 Years
Eligibility Inclusion Criteria:

- Juvenile idiopathic arthritis: Oligoarticular, polyarticular or systemic onset type.

- Informed consent from parents

- between 5-15 years of age

Exclusion Criteria:

- Other diagnoses that involves bones or cartilage

- Intraarticular steroid injections within 1 month of the trial investigation

Study Design

Observational Model: Cohort, Time Perspective: Cross-Sectional


Related Conditions & MeSH terms


Intervention

Device:
Ultrasonography
Scanning 5 joints bilaterally with an ultrasound scanner

Locations

Country Name City State
Denmark Pediatric research dept, Aarhus Universityhospital, Skejby Aarhus Region Midt

Sponsors (2)

Lead Sponsor Collaborator
University of Aarhus Aarhus University Hospital

Country where clinical trial is conducted

Denmark, 

Outcome

Type Measure Description Time frame Safety issue
Primary Joint cartilage thickness Joint catilage thickness measured by ultrasonography: knee, ankle, wrist, metacarpophalangeal and proximal interphalangeal joints by MRI: one knee by plain radiographs: knee, ankel and wrist 1.5 years No
Secondary Level of different biomarkers in serum and urine Level of bone- and cartilage-degradation biomarkers in serum and urine. COMP, CTX-II, RANKL/OPG, PYD/DPD 1.5 years No
See also
  Status Clinical Trial Phase
Completed NCT00891046 - An Open-label Extension Study of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis and Active Systemic Manifestations Manifestations and Response Characterization Study in Canakinumab Treatment-naïve Patients With Active SJIA With and Without Fever. Phase 3
Completed NCT02334748 - A Study of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis or Hereditary Periodic Fevers Who Participated in the CACZ885G2301E1, CACZ885G2306 or CACZ885N2301 Studies Phase 3
Completed NCT01803321 - Study to Evaluate the Safety and Tolerability of Two Doses of Rilonacept in Pediatric Subjects With Active Systemic Juvenile Idiopathic Arthritis (SJIA) Phase 1
Completed NCT00144664 - Study of MRA for Polyarticular Juvenile Idiopathic Arthritis (pJIA) Phase 3
Completed NCT02396212 - Study of Efficacy and Safety of Canakinumab in Japanese Patients With SJIA Phase 3
Completed NCT00144599 - Study of MRA for Systemic Juvenile Idiopathic Arthritis (sJIA) Phase 3
Terminated NCT00886769 - Single-dose Study to Assess Efficacy of Canakinumab (ACZ885) in Patients With Active Juvenile Idiopathic Arthritis (SJIA) Phase 3
Completed NCT00144612 - Long-term Treatment Study of MRA for Systemic Juvenile Idiopathic Arthritis (sJIA) Phase 3
Withdrawn NCT01676948 - An Open-label, Multi-arm, Non-comparative Safety and Tolerability Study of Canakinumab (ACZ885) in Patients With Active Systemic Juvenile Idiopathic Arthritis (SJIA) Phase 3
Recruiting NCT04088396 - A Study of Baricitinib (LY3009104) in Participants From 1 Year to Less Than 18 Years Old With sJIA Phase 3
Recruiting NCT05027373 - Safety, Tolerability and Pharmacokinetic of Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection Phase 1